NCT01486459View on ClinicalTrials.gov

A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer

NATerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2014

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Lithium

250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.

Trial Locations (2)

3189

Peter MacCallum Cancer Centre, Moorabbin

3220

Barwon Health, Geelong

Sponsors

Lead Sponsor

Barwon Health
All Listed Sponsors
collaborator

Deakin University

OTHER

collaborator

Peter MacCallum Cancer Centre, Australia

OTHER

lead

Barwon Health

OTHER_GOV

NCT01486459 - A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter